Michael Rosen named chief communications officer at Pancreatic Cancer Action Network

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Michael Rosen was named chief communications officer at the Pancreatic Cancer Action Network.

One of Rosen’s key roles will be increasing awareness about the organization’s ground breaking research and clinical initiatives like Precision Promise, a revolutionary clinical trial that will dramatically accelerate progress and bring promising therapies to patients faster.

Most recently, Rosen served as executive vice president of marketing and communications for the Mental Health Association of New York City, where he managed all marketing, communications strategies and development.

Between 2013 and 2016, Rosen led strategic communications for Autism Speaks, the world’s largest autism advocacy organization.

Prior to entering the nonprofit sector, Rosen was the executive producer first of The Saturday Early Show and then CBS This Morning Saturday. At ABC News, Rosen was second in charge for the network’s Peabody Award-winning coverage of 9/11, and covered the war in Kosovo on location. Rosen has won three Emmy Awards, two Peabody Awards and four DuPont Awards.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login